Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by Wolfe Research from a “peer perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, Marketbeat reports. Citigroup restated an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 17th. Get Madrigal Pharmaceuticals alerts:Read Our Latest Research Report on MDGLMadrigal Pharmaceuticals Price PerformanceMadrigal Pharmaceuticals stock opened at $482.00 on Tuesday. Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. Featured ArticlesReceive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.